Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-24T14:57:25.987Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder

Published online by Cambridge University Press:  02 January 2018

Erik Joas ,
Alina Karanti ,
Jie Song ,
Guy M. Goodwin ,
Paul Lichtenstein  and
Mikael Landén
Erik Joas
Affiliation:
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Alina Karanti
Affiliation:
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Jie Song
Affiliation:
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
Guy M. Goodwin
Affiliation:
Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
Paul Lichtenstein
Affiliation:
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
Mikael Landén
Affiliation:
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Gothenburg and Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Clinical trials have examined the efficacy of drugs to prevent relapse in patients with bipolar disorder, however, their design often limits generalisation to routine clinical practice.

Aims

To estimate the effectiveness of drugs used for maintenance treatment in bipolar disorder.

Method

We used national registers to identify 35022 individuals diagnosed with bipolar disorder and information on lithium, valproate, carbamazepine, lamotrigine, quetiapine and olanzapine treatment from 2006 to 2009. The main outcome was psychiatric hospital admissions. We used stratified cox regression to compare periods on and off medication within the same individual.

Results

Medication with lithium, valproate, lamotrigine, olanzapine and quetiapine was associated with reduced rates of admission to hospital. Lithium was more effective than quetiapine and olanzapine. The effects of specific drugs depended on the polarity of the mood episode.

Conclusions

Our findings complement results from randomised controlled trails, but suggest that lithium is more effective than both quetiapine and olanzapine in routine clinical practice.

Type
Papers
Information
The British Journal of Psychiatry , Volume 210 , Issue 3 , March 2017 , pp. 197 - 202
Copyright
Copyright © Royal College of Psychiatrists, 2017 

Footnotes

Declaration of interest

A.K. declares that, over the past 36 months, she has received lecture honoraria from Eli Lilly Sweden. M.L. declares that, over the past 36 months, he has received lecture honoraria from Biophausia Sweden, Servier Sweden, AstraZeneca. G.M.G. has held grants from Servier, received honoraria for speaking or chairing educational meetings from Abbvie, AZ, GSK, Lilly, Lundbeck, Medscape, Servier, and advised AZ, Cephalon/Teva, Lundbeck, Merck, Otsuka, P1vital, Servier, Sunovion and Takeda, and holds shares in P1vital.

References

1 National Institute for Clinical Excellence (NICE). Bipolar Disorder: Assessment and Management. NICE, 2014 (https://www.nice.org.uk/guidance/cg185).Google Scholar
2 Miura, T, Noma, H, Furukawa, TA, Mitsuyasu, H, Tanaka, S, Stockton, S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2014; 1: 351–9.Google Scholar
3 Goodwin, FK, Jamison, KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression: Bipolar Disorders and Recurrent Depression. Oxford University Press, 2007.Google Scholar
4 Rothwell, PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 2005; 365: 82–93.Google Scholar
5 Licht, R, Gouliaev, G, Vestergaard, P, Frydenberg, M. Generalisability of results from randomised drug trials. A trial on antimanic treatment. Br J Psychiatry 1997; 170: 264–7.Google Scholar
6 Tohen, M, Greil, W, Calabrese, JR, Sachs, GS, Yatham, LN, Oerlinghausen, BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281–90.Google Scholar
7 Geddes, JR, Goodwin, GM, Rendell, J, Azorin, J-M, Cipriani, A, Ostacher, MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385–95.Google Scholar
8 Licht, RW, Nielsen, JN, Gram, LF, Vestergaard, P, Bendz, H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010; 12: 483–93.Google Scholar
9 Whitaker, R, Cosgrove, L. Psychiatry Under the Influence: Institutional Corruption, Social Injury, and Prescriptions for Reform. Palgrave Macmillan, 2015.Google Scholar
10 Kessing, LV, Hellmund, G, Geddes, JR, Goodwin, GM, Andersen, PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011; 199: 57–63.Google Scholar
11 Kessing, LV, Hellmund, G, Andersen, PK. An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacol 2012; 26: 644–52.Google Scholar
12 Simhandl, C, König, B, Amann, BL. A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients. J Clin Psychiatry 2014; 75: 254–63.Google Scholar
13 Lichtenstein, P, Halldner, L, Zetterqvist, J, Sjolander, A, Serlachius, E, Fazel, S, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012; 367: 2006–14.Google Scholar
14 Socialstyrelsen (The National Board of Health and Welfare). Uppgifter om Psykiatrisk vård i Patientregistret [Data on Psychiatric Care in the Patient Register]. Socialstyrelsen, 2014 (http://www.socialstyrelsen.se/publikationer2014/2014-2-14).Google Scholar
15 Karanti, A, Bobeck, C, Osterman, M, Kardell, M, Tidemalm, D, Runeson, B, et al. Gender differences in the treatment of patients with bipolar disorder: A study of 7354 patients. J Affect Disord 2015; 174: 303–9.Google Scholar
16 Sellgren, C, Landen, M, Lichtenstein, P, Hultman, CM, Langstrom, N. Validity of bipolar disorder hospital discharge diagnoses: file review and multiple register linkage in Sweden. Acta Psychiatr Scand 2011; 124: 447–53.Google Scholar
17 World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD–8). WHO, 1967.Google Scholar
18 World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD–9). WHO, 1978.Google Scholar
19 World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.Google Scholar
20 Fazel, S, Zetterqvist, J, Larsson, H, Långström, N, Lichtenstein, P. Antipsychotics, mood stabilisers, and risk of violent crime. Lancet 2014; 384: 1206–14.Google Scholar
21 Molero, Y, Lichtenstein, P, Zetterqvist, J, Gumpert, CH, Fazel, S. Selective serotonin reuptake inhibitors and violent crime: a cohort study. PLoS Med 2015; 12: e1001875.Google Scholar
22 Benjamini, Y, Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289–300.Google Scholar
23 Leifeld, P. texreg: Conversion of statistical model output in R to LATEX and HTML tables. J Stat Softw 2013; 55: 1–24.Google Scholar
24 Hayes, JF, Marston, L, Walters, K, Geddes, JR, King, M, Osborn, DPJ. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry 2016; 15: 53–8.Google Scholar
25 Vieta, E, Günther, O, Locklear, J, Ekman, M, Miltenburger, C, Chatterton, ML, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011; 14: 1029–49.Google Scholar
26 Smith, LA, Cornelius, V, Warnock, A, Bell, A, Young, AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disorders 2007; 9: 394–412.Google Scholar
27 Deshauer, D, Fergusson, D, Duffy, A, Albuquerque, J, Grof, P. Re-evaluation of randomized control trials of lithium monotherapy: a cohort effect. Bipolar Disord 2005; 7: 382–7.Google Scholar
28 Goodwin, GM, Bowden, CL, Calabrese, JR, Grunze, H, Kasper, S, White, R, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432–41.Google Scholar
29 Hirschfeld, R, Kasper, S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 2004; 7: 507–22.Google Scholar
Supplementary material: PDF

Joas et al. supplementary material

Supplementary Tables S1-S13

Download Joas et al. supplementary material(PDF)
PDF 127.1 KB
Submit a response

eLetters

No eLetters have been published for this article.